{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:09:42Z","timestamp":1784045382878,"version":"3.55.0"},"reference-count":113,"publisher":"Elsevier","isbn-type":[{"value":"9780443345234","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apcsb.2026.04.003","type":"book-chapter","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:23:26Z","timestamp":1782473006000},"page":"321-349","source":"Crossref","is-referenced-by-count":0,"title":["Molecular characterization and experimental models of chordoma: Foundations for rational therapy development"],"prefix":"10.1016","author":[{"given":"Christian","family":"Godinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilija","family":"Sagaityte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Aina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn C\u00f3rdova","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya L.","family":"Gokaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Zadnik Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Martinez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apcsb.2026.04.003_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13036-020-0227-7","article-title":"Alginate-based hydrogels as drug delivery vehicles in cancer treatment and their applications in wound dressing and 3D bioprinting","volume":"14","author":"Abasalizadeh","year":"2020","journal-title":"Journal of Biological Engineering"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl3674","article-title":"Personalized chordoma organoids for drug discovery studies","volume":"8","author":"Al Shihabi","year":"2022","journal-title":"Science Advances"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2024.1375567","article-title":"Role of immunotherapy in treatment refractory chordomas: Review of current evidence","volume":"11","author":"Alexander","year":"2024","journal-title":"Frontiers in Surgery"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-27893-y","article-title":"AI-assisted identification of innovative phytochemicals from Aizoon canariense aimed at brachyury protein in chordoma: A computational strategy","volume":"15","author":"Alshammari","year":"2025","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70026-w","article-title":"Synergistic drug combinations and machine learning for drug repurposing in chordoma","volume":"10","author":"Anderson","year":"2020","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/PAS.0000000000000741","article-title":"SMARCB1\/INI1 involvement in pediatric chordoma: A mutational and immunohistochemical analysis","volume":"41","author":"Antonelli","year":"2017","journal-title":"The American Journal of Surgical Pathology"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/jcm10051054","article-title":"Chordoma\u2014Current understanding and modern treatment paradigms","volume":"10","author":"Barber","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/514753","article-title":"Brachyury: A diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers","volume":"2014","author":"Barresi","year":"2014","journal-title":"Disease Markers"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-017-2224-x","article-title":"Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas","volume":"472","author":"Bell","year":"2018","journal-title":"Virchows Archiv"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.003_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14101028","article-title":"Impact of CDK inhibitors on TBXT expression in chordoma cell lines including the first stable cell line of a high-grade chordoma","volume":"14","author":"Bette","year":"2024","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib11","first-page":"374","article-title":"Immune checkpoint inhibitors have clinical activity in patients with recurrent chordoma","volume":"45","author":"Bishop","year":"2022","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): Analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"The Lancet Oncology"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdv300","article-title":"Sorafenib in patients with locally advanced and metastatic chordomas: A phase II trial of the French Sarcoma Group (GSF\/GETO)","volume":"26","author":"Bompas","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1330254","article-title":"Animal model considerations for chordoma research: Reproducing the tumor microenvironment in vivo with humanized mice","volume":"14","author":"Campilan","year":"2024","journal-title":"Frontiers in Oncology"},{"issue":"16","key":"10.1016\/bs.apcsb.2026.04.003_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70033","article-title":"Mutational analysis of primary and advanced chordoma tissue using next\u2010generation sequencing","volume":"131","author":"Chan","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.003_bib16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s12032-014-0886-7","article-title":"Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis","volume":"31","author":"Chen","year":"2014","journal-title":"Medical Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fonc.2020.00961","article-title":"The roles of embryonic transcription factor BRACHYURY in tumorigenesis and progression","volume":"10","author":"Chen","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib18","article-title":"Immune microenvironment and immunotherapy for chordoma","volume":"14","author":"Chen","year":"2024","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101283","article-title":"Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1","volume":"9","author":"Choy","year":"2014","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/bs.apcsb.2026.04.003_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/atm.2016.11.82","article-title":"Aldehyde dehydrogenases in cancer stem cells: Potential as therapeutic targets","volume":"4","author":"Clark","year":"2016","journal-title":"Annals of Translational Medicine"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1634\/theoncologist.2019-0932","article-title":"Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors","volume":"25","author":"Collins","year":"2020","journal-title":"The Oncologist"},{"issue":"22","key":"10.1016\/bs.apcsb.2026.04.003_bib22","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1002\/cncr.35477","article-title":"A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma","volume":"130","author":"Cote","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib23","first-page":"113","article-title":"Frequent alterations in p16\/CDKN2A identified by immunohistochemistry and FISH in chordoma","volume":"6","author":"Cottone","year":"2020","journal-title":"The Journal of Pathology: Clinical Research"},{"issue":"10","key":"10.1016\/bs.apcsb.2026.04.003_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205752","article-title":"The development of the human notochord","volume":"13","author":"de Bree","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.003_bib25","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.humpath.2012.11.024","article-title":"Tyrosine kinase receptor expression in chordomas: Phosphorylated AKT correlates inversely with outcome","volume":"44","author":"de Castro","year":"2013","journal-title":"Human Pathology"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.003_bib26","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1002\/onco.13720","article-title":"Randomized, double\u2010blind, placebo\u2010controlled phase II study of yeast\u2010brachyury vaccine (GI\u20106301) in combination with standard\u2010of\u2010care radiotherapy in locally advanced, unresectable chordoma","volume":"26","author":"DeMaria","year":"2021","journal-title":"The Oncologist"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.003_bib27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00262-022-03152-1","article-title":"Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas","volume":"71","author":"Duan","year":"2022","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib28","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1039\/C5MB00101C","article-title":"The PI3K\/AKT\/mTOR interactive pathway","volume":"11","author":"Ersahin","year":"2015","journal-title":"Molecular Biosystems"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S0016672300010168","article-title":"\u2018Nude\u2019, a new hairless gene with pleiotropic effects in the mouse","volume":"8","author":"Flanagan","year":"1966","journal-title":"Genetical Research"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/jor.23320","article-title":"Chordoma\u2010derived cell line U\u2010CH1\u2010N recapitulates the biological properties of notochordal nucleus pulposus cells","volume":"34","author":"Fujita","year":"2016","journal-title":"Journal of Orthopaedic Research"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Molecular Cancer"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-024-04920-y","article-title":"Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma","volume":"172","author":"Godinez","year":"2025","journal-title":"Journal of Neuro-oncology"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.003_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3171\/2015.7.SPINE15201","article-title":"Mobile spine chordoma: Results of 166 patients from the AOSpine knowledge forum tumor database","volume":"24","author":"Gokaslan","year":"2016","journal-title":"Journal of Neurosurgery. Spine"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib34","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1158\/1078-0432.CCR-18-3133","article-title":"Immunologic correlates of the abscopal effect in a SMARCB1\/INI1-negative Poorly Differentiated Chordoma after EZH2 inhibition and radiotherapy","volume":"25","author":"Gounder","year":"2019","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib35","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41467-019-09633-9","article-title":"Defective homologous recombination DNA repair as therapeutic target in advanced chordoma","volume":"10","author":"Gr\u00f6schel","year":"2019","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.003_bib36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/neuonc\/nox241","article-title":"Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma","volume":"20","author":"Hao","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8886095","article-title":"Current status of alginate in drug delivery","volume":"2020","author":"Hariyadi","year":"2020","journal-title":"Advances in Pharmacological and Pharmaceutical Sciences"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.003_bib38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2326-6066.CIR-15-0119","article-title":"Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury","volume":"3","author":"Heery","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.04.003_bib39","first-page":"572","article-title":"Effectiveness of cetuximab\/gefitinib in the therapy of a sacral chordoma","volume":"29","author":"Hof","year":"2006","journal-title":"Onkologie"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fneur.2020.00657","article-title":"Translational windows in chordoma: A target appraisal","volume":"11","author":"Hoffman","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cancers17030536","article-title":"Genomic characterization of chordoma: Insights from the AACR project GENIE database","volume":"17","author":"Hsia","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.003_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/2011.5.JNS11185","article-title":"Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target: Laboratory investigation","volume":"115","author":"Hsu","year":"2011","journal-title":"Journal of Neurosurgery"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib43","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/carcin\/bgu014","article-title":"The FGFR\/MEK\/ERK\/brachyury pathway is critical for chordoma cell growth and survival","volume":"35","author":"Hu","year":"2014","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.003_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105051","article-title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies","volume":"10","author":"Janku","year":"2025","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.003_bib45","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1134\/S0006297918110019","article-title":"Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications","volume":"83","author":"Jiao","year":"2018","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biocel.2014.03.014","article-title":"Interdependent epidermal growth factor receptor signalling and trafficking","volume":"51","author":"Jones","year":"2014","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1748-717X-6-116","article-title":"In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs","volume":"6","author":"Kato","year":"2011","journal-title":"Radiation Oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib48","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1038\/s41467-023-42151-3","article-title":"Conserved enhancers control notochord expression of vertebrate Brachyury","volume":"14","author":"Kemmler","year":"2023","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.003_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018846","article-title":"Recurrent chromosomal copy number alterations in sporadic chordomas","volume":"6","author":"Le","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.003_bib50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: New modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"25","key":"10.1016\/bs.apcsb.2026.04.003_bib51","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1021\/bi200642e","article-title":"The regulatory mechanisms of tumor suppressor P16INK4A and relevance to cancer","volume":"50","author":"Li","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib52","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.2147\/CMAR.S250611","article-title":"Long non-coding RNA KCNQ1OT1 promotes multidrug resistance in chordoma by functioning as a molecular sponge of miR-27b-3p and subsequently increasing ATF2 expression","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Management and Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/cas.13875","article-title":"Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor\/AKT pathway in spinal chordoma","volume":"110","author":"Liang","year":"2019","journal-title":"Cancer Science"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/02841860802266672","article-title":"Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib","volume":"48","author":"Lind\u00e8n","year":"2009","journal-title":"Acta Oncologica"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.003_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.gendis.2023.101133","article-title":"EZH2 is a prognostic factor associated with tumor stemness and immune infiltration in skull base chordoma","volume":"11","author":"Liu","year":"2023","journal-title":"Genes & Diseases"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/cells10020399","article-title":"Aldehyde dehydrogenase, a therapeutic target in chordoma: Analysis in 3D cellular models","volume":"10","author":"Locquet","year":"2021","journal-title":"Cells"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659662","article-title":"B7-H3 as a target for CAR-T cell therapy in skull base chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.003_bib58","article-title":"Current understanding of brachyury in chordoma","volume":"1878","author":"Ma","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA)\u00a0- Reviews on Cancer"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1535-7163.MCT-17-0324","article-title":"Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury","volume":"17","author":"Magnaghi","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11060-014-1637-5","article-title":"PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment","volume":"121","author":"Mathios","year":"2015","journal-title":"Journal of Neuro-oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdaa173","article-title":"The mutational landscape of spinal chordomas and their sensitive detection using circulating tumor DNA","volume":"3","author":"Mattox","year":"2021","journal-title":"Neuro-Oncology Advances"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-020-03418-7","article-title":"Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy","volume":"147","author":"Michmerhuizen","year":"2020","journal-title":"Journal of Neuro-oncology"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1338235","article-title":"First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies","volume":"6","author":"Migliorini","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.carbpol.2017.10.040","article-title":"Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics","volume":"181","author":"Mirti\u010d","year":"2018","journal-title":"Carbohydrate Polymers"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer\u2014Biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib66","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s40883-024-00378-6","article-title":"Characterization of the pH-dependent disintegration of chemically modified alginate hydrogels","volume":"11","author":"Morningstar","year":"2025","journal-title":"Regenerative Engineering and Translational Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib67","article-title":"From notochord formation to hereditary chordoma: The many roles of Brachyury","volume":"2013","author":"Nibu","year":"2013","journal-title":"BioMed Research International"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib69","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3171\/2016.10.JNS16877","article-title":"UM-Chor1: Establishment and characterization of the first validated clival chordoma cell line","volume":"128","author":"Owen","year":"2018","journal-title":"Journal of Neurosurgery"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.003_bib70","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3390\/cancers14061486","article-title":"Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft","volume":"14","author":"Passeri","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-016-0462-4","article-title":"Patient-derived xenografts: A relevant preclinical model for drug development","volume":"35","author":"Pompili","year":"2016","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.003_bib72","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/sj.bjc.6605019","article-title":"Potential therapeutic targets for chordoma: PI3K\/AKT\/TSC1\/TSC2\/mTOR pathway","volume":"100","author":"Presneau","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/path.2816","article-title":"Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: A genetic and functional-based study","volume":"223","author":"Presneau","year":"2011","journal-title":"The Journal of Pathology"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cells6020013","article-title":"Activation of the EGF receptor by ligand binding and oncogenic mutations: The \u201cRotation Model\u201d","volume":"6","author":"Purba","year":"2017","journal-title":"Cells"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.04.003_bib75","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cac2.12224","article-title":"Tumor organoids: Synergistic applications, current challenges, and future prospects in cancer therapy","volume":"41","author":"Qu","year":"2021","journal-title":"Cancer Communications"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/pharmaceutics14030574","article-title":"Drug delivery strategies and biomedical significance of hydrogels: Translational considerations","volume":"14","author":"Raina","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/genbio.2024.0048","article-title":"Repurposing a combination of palbociclib and afatinib halts chordoma growth in a mouse model","volume":"4","author":"Raman","year":"2025","journal-title":"GEN Biotechnology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1160764","article-title":"SMARCB1\/INI1 loss in skull base conventional chordomas: A clinicopathological and molecular analysis","volume":"13","author":"Righi","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib79","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.gde.2013.11.012","article-title":"Organoid cultures for the analysis of cancer phenotypes","volume":"24","author":"Sachs","year":"2014","journal-title":"Current Opinion in Genetics & Development"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/gcc.1184","article-title":"Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1","volume":"32","author":"Scheil","year":"2001","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"12","key":"10.1016\/bs.apcsb.2026.04.003_bib81","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/jor.22447","article-title":"Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis","volume":"31","author":"Scheipl","year":"2013","journal-title":"Journal of Orthopaedic Research"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.003_bib82","doi-asserted-by":"crossref","first-page":"708","DOI":"10.5435\/00124635-200911000-00005","article-title":"Chordoma of the sacrum and vertebral bodies","volume":"17","author":"Sciubba","year":"2009","journal-title":"The Journal of the American Academy of Orthopaedic Surgeons"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nec.2007.09.006","article-title":"Chordoma of the spinal column","volume":"19","author":"Sciubba","year":"2008","journal-title":"Neurosurgery Clinics of North America"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib84","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/cancers15071977","article-title":"Prognostic relevance and in vitro targeting of concomitant PTEN and p16 deficiency in chordomas","volume":"15","author":"Seeling","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/bs.apcsb.2026.04.003_bib85","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.2818","article-title":"The role of epidermal growth factor receptor in chordoma pathogenesis: A potential therapeutic target","volume":"223","author":"Shalaby","year":"2011","journal-title":"The Journal of Pathology"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib86","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41591-018-0312-3","article-title":"Small-molecule targeting of brachyury transcription factor addiction in chordoma","volume":"25","author":"Sharifnia","year":"2019","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib87","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/dvdy.10480","article-title":"T-box genes in early embryogenesis","volume":"229","author":"Showell","year":"2004","journal-title":"Developmental Dynamics: An Official Publication of the American Association of Anatomists"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.003_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078895","article-title":"Erlotinib inhibits growth of a patient-derived chordoma xenograft","volume":"8","author":"Siu","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.003_bib89","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3171\/2011.12.JNS111123","article-title":"Establishment and characterization of a primary human chordoma xenograft model","volume":"116","author":"Siu","year":"2012","journal-title":"Journal of Neurosurgery"},{"issue":"9","key":"10.1016\/bs.apcsb.2026.04.003_bib90","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.2011.35.3656","article-title":"Phase II study of imatinib in advanced chordoma","volume":"30","author":"Stacchiotti","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1016\/bs.apcsb.2026.04.003_bib91","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1002\/cncr.31685","article-title":"Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study","volume":"124","author":"Stacchiotti","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib92","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/annonc\/mdt117","article-title":"Phase II study on lapatinib in advanced EGFR-positive chordoma\u2020","volume":"24","author":"Stacchiotti","year":"2013","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib93","doi-asserted-by":"crossref","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","article-title":"Tazemetostat: EZH2 Inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"issue":"23","key":"10.1016\/bs.apcsb.2026.04.003_bib94","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1158\/1078-0432.CCR-06-1584","article-title":"Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas","volume":"12","author":"Tamborini","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib95","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/neuonc\/noq003","article-title":"Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas","volume":"12","author":"Tamborini","year":"2010","journal-title":"Neuro-Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib96","series-title":"StatPearls","article-title":"Chordoma","author":"Tenny","year":"2023"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.1011845","article-title":"PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells","volume":"9","author":"Tian","year":"2022","journal-title":"Frontiers in Surgery"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008138","article-title":"Multimodal profiling of chordoma immunity reveals distinct immune contextures","volume":"12","author":"Van Oost","year":"2024","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"18","key":"10.1016\/bs.apcsb.2026.04.003_bib99","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-14-3270","article-title":"Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4\/6 cell-cycle pathway","volume":"75","author":"Von Witzleben","year":"2015","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.apcsb.2026.04.003_bib100","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: Current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"4","key":"10.1016\/bs.apcsb.2026.04.003_bib101","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajpath.2022.12.012","article-title":"SMARCB1 loss in poorly differentiated chordomas drives tumor progression","volume":"193","author":"Walhart","year":"2023","journal-title":"The American Journal of Pathology"},{"issue":"6","key":"10.1016\/bs.apcsb.2026.04.003_bib102","article-title":"Advances in the development of chordoma models for drug discovery and precision medicine","volume":"1877","author":"Walker","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA)\u00a0- Reviews on Cancer"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib103","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/gcc.22362","article-title":"Genomic aberrations frequently alter chromatin regulatory genes in chordoma","volume":"55","author":"Wang","year":"2016","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib104","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/cancers15010264","article-title":"Immunotherapy as a promising option for the treatment of advanced chordoma: A systemic review","volume":"15","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/bs.apcsb.2026.04.003_bib105","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41419-024-07109-3","article-title":"Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI\/SNF loss-of-function tumors","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death & Disease"},{"issue":"8","key":"10.1016\/bs.apcsb.2026.04.003_bib106","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archotol.131.8.707","article-title":"Differential expression of epidermal growth factor receptor, c-Met, and HER2\/neu in chordoma compared with 17 other malignancies","volume":"131","author":"Weinberger","year":"2005","journal-title":"Archives of Otolaryngology\u2013Head & Neck Surgery"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41698-021-00238-4","article-title":"Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury","volume":"5","author":"Williamson","year":"2021","journal-title":"NPJ Precision Oncology"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib108","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.2147\/OTT.S252990","article-title":"Deficiency of PTEN and CDKN2A tumor-suppressor genes in conventional and chondroid chordomas: Molecular characteristics and clinical relevance","volume":"13","author":"Yang","year":"2020","journal-title":"OncoTargets and Therapy"},{"issue":"5","key":"10.1016\/bs.apcsb.2026.04.003_bib109","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cpr.12204","article-title":"Epigenetic deregulations in chordoma","volume":"48","author":"Yu","year":"2015","journal-title":"Cell Proliferation"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41421-022-00459-2","article-title":"Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Discovery"},{"key":"10.1016\/bs.apcsb.2026.04.003_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1029670","article-title":"A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma","volume":"12","author":"Zhao","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2026.04.003_bib112","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/path.5739","article-title":"AZD8055 enhances in vivo efficacy of afatinib in chordomas","volume":"255","author":"Zhao","year":"2021","journal-title":"The Journal of Pathology"},{"issue":"7","key":"10.1016\/bs.apcsb.2026.04.003_bib113","first-page":"3274","article-title":"Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis","volume":"8","author":"Zou","year":"2016","journal-title":"American Journal of Translational Research"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Molecular targets and therapeutic design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162326000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162326000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:37:14Z","timestamp":1784043434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162326000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443345234"],"references-count":113,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2026.04.003","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}